Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis

AlFadhli, Suad; AlFailakawi, Asma'a; Ghanem, A.

doi:10.1111/1756-185x.12393

Cited by 14 publications

(12 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th17 cells are now defined as a separate CD4+ T-cell subset distinct from the Th1 and Th2 cells, driving inflammatory responses in several T-cell driven autoimmune diseases [ 24 – 26 ]. More recently, multiple lines of evidence have indicated that Th17 cells are involved in lung cancer [ 27 – 29 ].…”

Section: Discussionmentioning

confidence: 99%

Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients

Duan

Ning

et al. 2015

Mediators of Inflammation

View full text Add to dashboard Cite

The presence of Th17 cells and IL-27 is observed in a variety of inflammatory associated cancers. However, there are some data on the role of Th17 cells and IL-27 in the regulation of immune reactions in non-small-cell lung cancer (NSCLC). The aim of this study is to assess the variation of Th17 cells and IL-27 in the peripheral blood (PB) of patients with NSCLC. The proportion of Th17 cells in peripheral blood mononuclear cells (PBMCs) was evaluated by flow cytometry. The serum concentrations of IL-27 and IL-17 were measured by enzyme-linked immunosorbent assay (ELISA). The mRNA expression of RORγt and IL-27 in the peripheral blood was examined by real-time quantitative polymerase chain reaction (QPCR). Expression of IL-27 was lower in NSCLC patients compared with normal controls. The frequency of Th17 cells was increased in NSCLC patients, accompanied by the upregulation of IL-17 and RORγt. IL-27 negatively correlated with the number of Th17 cells and the RORγt mRNA. Our results indicate that IL-27 might inhibit Th17 differentiation in NSCLC patients and better understanding of the regulatory effects of IL-27 on Th17 cells may shed light on potential new targets in cancer prevention and therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients

Duan

Ning

et al. 2015

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…50 Results revealed 14 genes ( IL-17A , IL-17C , IL-17D , IL-17F , IL-12RB2 , IL-23R , IL-18 , RORC , STAT4 , TRAF6 , MMP3 , CCL2 , CCL20 , and CXCL5 ) that were differentially expressed in SLE and LN patients when compared to healthy individuals. 50 The study also revealed an elevated levels of serum IL-17A and IL-17F in LN patients when compared to SLE patients. 50 In the second study, a genome-wide differential expression analysis of Arab female SLE and LN patients revealed seven candidate genes in SLE and 36 in LN, whose role in the pathogenesis of SLE and LN need to be investigated further.…”

Section: Genetic Studies Of Sle/ln In the Gcc Regionmentioning

confidence: 97%

“…50–52 In the first study, a panel of 84 genes involved in the Th17-related regulatory network was investigated and the expression levels of serum interleukin (IL)-17A and IL-17F were explored in SLE and LN Arab patients. 50 Results revealed 14 genes ( IL-17A , IL-17C , IL-17D , IL-17F , IL-12RB2 , IL-23R , IL-18 , RORC , STAT4 , TRAF6 , MMP3 , CCL2 , CCL20 , and CXCL5 ) that were differentially expressed in SLE and LN patients when compared to healthy individuals. 50 The study also revealed an elevated levels of serum IL-17A and IL-17F in LN patients when compared to SLE patients.…”

Section: Genetic Studies Of Sle/ln In the Gcc Regionmentioning

confidence: 99%

Lupus nephritis: A focus on the United Arab Emirates and the potential role of genetics

Tabouni

Ali

Aljaberi

et al. 2022

Lupus

View full text Add to dashboard Cite

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), characterized by chronic and progressive inflammation of the kidneys. As with many other autoimmune diseases, LN is a multifactorial disease caused by genetic and environmental factors. Globally, LN can affect around 60% of SLE patients, and it was observed to be less frequent and severe in Caucasian patients compared to other ethnic groups, including Arabs. Data on LN in the United Arab Emirates (UAE) are scattered and scarce in literature. Nevertheless, LN is common, occurring in around 43%–55% of SLE patients in the UAE. Anecdotally, the demographics and clinical features of SLE in the UAE have been distinct. However, the paucity of supporting literature makes it difficult to draw meaningful conclusions. Over the past two decades, there have been improvements in understanding the pathogenesis of LN; however, many cellular and molecular mechanisms which are implicated in the disease development and progression remain ambiguous. Investigating the clinical, pathological, and genetic characteristics of LN in different cohorts of patients is of importance for a better understanding of its pathogenesis, and thus improving its outcome. As a result, we acknowledge the need for large-scale epidemiological, clinical, and genetic investigation of LN cohorts in the UAE and surrounding regions.

show abstract

“…Studies of CCL20 in the blood of SLE patients are limited and conflicting. Pan et al 56 found no difference in CCL20 mRNA in circulating leukocytes between SLE patients and HCs, whereas AlFadhli et al 69 found a marked reduction in CCL20 in whole blood of SLE patients. This reduction seen in AlFadhli et al's study may be the result of treatment the patients received or the fact that there may be a degree of dilution in the starting cDNA with plasma and other nonleukocytes.…”

Section: B Cellsmentioning

confidence: 97%

“…Pan et al 56 . found no difference in CCL20 mRNA in circulating leukocytes between SLE patients and HCs, whereas AlFadhli et al 69 . found a marked reduction in CCL20 in whole blood of SLE patients.…”

Section: Introductionmentioning

confidence: 98%

CC chemokine receptor 6 (CCR6) in the pathogenesis of systemic lupus erythematosus

Lee

Körner

2020

Immunol Cell Biol

View full text Add to dashboard Cite

The CC chemokine receptor 6 (CCR6) and its sole chemokine ligand, CCL20, are an intriguing pair that have been implicated in a growing number of inflammatory, autoimmune and malignant disease processes. Recent observations have also highlighted this chemokine axis in the regulation of humoral immune responses. Through this review article, we explore the emerging links of CCR6-CCL20 with an archetypal autoimmune disease of humoral dysregulation: systemic lupus erythematosus (SLE). CCR6 is expressed prominently on several immune cells involved in the pathogenesis of SLE, such as dendritic cells and T-helper 17 cells. CCR6's expression is correlated with disease activity and serological markers of disease severity, suggesting a possible role in disease pathogenesis. However, there are numerous holes in our understanding of the functions of CCR6 and CCL20, and future studies are required to determine if there are any diagnostic, prognostic or monitoring roles for these important molecules.

show abstract

Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis

Cited by 14 publications

References 50 publications

Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients

Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients

Lupus nephritis: A focus on the United Arab Emirates and the potential role of genetics

CC chemokine receptor 6 (CCR6) in the pathogenesis of systemic lupus erythematosus

Contact Info

Product

Resources

About